Melissa Leung ESA-SRB-ANZOS 2025 in conjunction with ENSA

Abstracts this author is presenting:

• Tirzepatide treatment and achieving weight reduction >5%, SBP reduction >5 mmHg and non-HDL cholesterol reduction >10%: A post hoc analysis from the SURMOUNT-1 3-year trial — ANZOS Concurrent 16 Incretin Issues - Practical discussions for prescribing clinicians and others wanting answers